Percentage of JAK2V617F/JAK2total in the gDNA of various hematopoietic lineages isolated from patients with PV and healthy volunteers determined by real-time PCR
Donors* . | Granulocytes, % . | CD34+ cells, % . | CD33+ cells, % . | Gly-A+ cells, % . | CD19+ cells, % . | CD3+ cells, % . |
|---|---|---|---|---|---|---|
| PV1 | 73.0 | 68.9 | 50.2 | 17.8 | 32.8 | 0 |
| PV2 | 8.7 | 12.3 | 6.3 | 1.3 | 0 | 0 |
| PV3 | 64.6 | 67.5 | 34.0 | 25.9 | 0 | 0 |
| PV4 | 21.5 | 33.8 | 20.4 | 27.9 | 0 | 0 |
| PV7 | 37.2 | 38.9 | 33.5 | 48.4 | 0 | 0 |
| PV8 | 49.6 | 46.2 | 24.8 | 43.3 | 0 | 0 |
| PV9 | 100 | 98.2 | 100 | 97.2 | 34.7 | 7.6 |
| PV10 | 64.3 | 48.7 | 51.1 | 46.0 | 0 | 0 |
Donors* . | Granulocytes, % . | CD34+ cells, % . | CD33+ cells, % . | Gly-A+ cells, % . | CD19+ cells, % . | CD3+ cells, % . |
|---|---|---|---|---|---|---|
| PV1 | 73.0 | 68.9 | 50.2 | 17.8 | 32.8 | 0 |
| PV2 | 8.7 | 12.3 | 6.3 | 1.3 | 0 | 0 |
| PV3 | 64.6 | 67.5 | 34.0 | 25.9 | 0 | 0 |
| PV4 | 21.5 | 33.8 | 20.4 | 27.9 | 0 | 0 |
| PV7 | 37.2 | 38.9 | 33.5 | 48.4 | 0 | 0 |
| PV8 | 49.6 | 46.2 | 24.8 | 43.3 | 0 | 0 |
| PV9 | 100 | 98.2 | 100 | 97.2 | 34.7 | 7.6 |
| PV10 | 64.3 | 48.7 | 51.1 | 46.0 | 0 | 0 |
The purity of the CD19+ cells and CD3+ cells was 99% or greater. The purity of the other cell types was 95% or greater. Values are JAK2V617F mutant allele/JAK2 total allele × 100. JAK2V617F/JAK2total was calculated according to the mean ΔCt and the standard curve by real-time quantitative PCR.
The G-CSF—mobilized healthy subjects 1, 2, and 3 had 0% of JAK2V617F/JAK2total in the gDNA of various hematopoietic lineages.